Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Conivaptan for hepatic hemodynamics in cirrhosis
NCT00592475Phase 2Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Dec 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of conivaptan in Liver cirrhosis (LC) (3 arms), sponsored by Cumberland Pharmaceuticals. Primary endpoints: Hepatic Venous Pressure Gradient at 1.5 hours, Hepatic Blood Flow at 1.5 hours and 3 more. Started Dec 2007; status: completed.
02
Drugs
conivaptan
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT00592475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592475.